Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

“This cumulative clinical data […] strongly supports the earlier laboratory and epidemiological data, that GLP-1 receptor stimulation in the brain has neuroprotective effects relevant to the ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...